Disease · MONDO_0005347
Targets35
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 20 of 35
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PPARA | Peroxisome proliferator-activated receptor | 7 | Peroxisome proliferator-activated receptor agonist; Peroxisome proliferator-activated receptor alpha agonist | Phase 3 | https://conductscience.org/library/genes/5465 | Drugs and targets |
| APOC3 | Apolipoprotein C-III mRNA | 3 | Apolipoprotein C-III mRNA 3'UTR antisense inhibitor; Apolipoprotein C-III mRNA antisense inhibitor | Approval | https://conductscience.org/library/genes/345 | Drugs and targets |
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 3 | HMG-CoA reductase inhibitor | Phase 3 | https://conductscience.org/library/genes/3156 | Drugs and targets |
| PPARG | Peroxisome proliferator-activated receptor | 3 | Peroxisome proliferator-activated receptor agonist; Peroxisome proliferator-activated receptor gamma agonist | Phase 2 | https://conductscience.org/library/genes/5468 | Drugs and targets |
| ANGPTL3 | Angiopoietin like 3 (ANGPTL3) mRNA | 2 | Angiopoietin like 3 (ANGPTL3) mRNA antisense inhibitor; Angiopoietin-related protein 3 inhibitor | Phase 2 | https://conductscience.org/library/genes/27329 | Drugs and targets |
| LEPR | Leptin receptor | 2 | Leptin receptor agonist | Phase 3 | https://conductscience.org/library/genes/3953 | Drugs and targets |
| MTTP | Microsomal triglyceride transfer protein | 2 | Microsomal triglyceride transfer protein inhibitor | Phase 2 | https://conductscience.org/library/genes/4547 | Drugs and targets |
| P4HB | Microsomal triglyceride transfer protein | 2 | Microsomal triglyceride transfer protein inhibitor | Phase 2 | https://conductscience.org/library/genes/5034 | Drugs and targets |
| ADORA1 | Adenosine receptor A1 | 1 | Adenosine A1 receptor partial agonist | Phase 1 | https://conductscience.org/library/genes/134 | Drugs and targets |
| ASGR1 | Asialoglycoprotein receptor 1 | 1 | Asialoglycoprotein receptor 1 binding agent | Phase 2 | https://conductscience.org/library/genes/432 | Drugs and targets |
| CYP3A4 | Cytochrome P450 3A | 1 | Cytochrome P450 3A inhibitor | Phase 1 | https://conductscience.org/library/genes/1576 | Drugs and targets |
| CYP3A43 | Cytochrome P450 3A | 1 | Cytochrome P450 3A inhibitor | Phase 1 | https://conductscience.org/library/genes/64816 | Drugs and targets |
| CYP3A5 | Cytochrome P450 3A | 1 | Cytochrome P450 3A inhibitor | Phase 1 | https://conductscience.org/library/genes/1577 | Drugs and targets |
| CYP3A7 | Cytochrome P450 3A | 1 | Cytochrome P450 3A inhibitor | Phase 1 | https://conductscience.org/library/genes/1551 | Drugs and targets |
| DGAT1 | Diacylglycerol O-acyltransferase 1 | 1 | Diacylglycerol O-acyltransferase 1 inhibitor | Phase 3 | https://conductscience.org/library/genes/8694 | Drugs and targets |
| INSR | Insulin receptor | 1 | Insulin receptor agonist | Unknown | https://conductscience.org/library/genes/3643 | Drugs and targets |
| LIPF | Gastric triacylglycerol lipase | 1 | Gastric lipase inhibitor | Phase 2 | https://conductscience.org/library/genes/8513 | Drugs and targets |
| MC4R | Melanocortin receptor 4 | 1 | Melanocortin receptor 4 agonist | Phase 2 | https://conductscience.org/library/genes/4160 | Drugs and targets |
| PNLIP | Pancreatic triacylglycerol lipase | 1 | Pancreatic lipase inhibitor | Phase 2 | https://conductscience.org/library/genes/5406 | Drugs and targets |
| PPARD | Peroxisome proliferator-activated receptor | 1 | Peroxisome proliferator-activated receptor agonist | Unknown | https://conductscience.org/library/genes/5467 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005347/targets